Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00572169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Aug 2026 to Aug 2027v23
  2. Primary and study completion dates: Aug 2025 to Aug 2026v22
  3. Primary and study completion dates: Aug 2024 to Aug 2025v21
  4. 2 versions Re-verified since Jun 8, 2022, no change to tracked fieldsv19-v20
  5. Primary and study completion dates: Aug 2021 to Aug 2024v18
Show 16 earlier versionsHide 16 earlier versions
  1. Re-verified, no change to tracked fieldsv17
  2. Primary and study completion dates: Aug 2019 to Aug 2021v16
  3. Primary and study completion dates: Aug 2018 to Aug 2019v15
  4. Primary and study completion dates: Aug 2017 to Aug 2018v14
  5. Primary and study completion dates: Aug 2016 to Aug 2017
    • Interventions: Bortezomib (Velcade) (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Dexamethasone (Drug), Doxorubicin (Drug), Etoposide (Drug)… to Adriamycin (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Dexamethasone (Drug), Etoposide (Drug), Thalidomide (Drug), Velcade (Drug)
    • Study site revised
    v13
  6. Re-verified, no change to tracked fieldsv12
  7. Primary and study completion dates: Aug 2015 to Aug 2016v11
  8. Primary and study completion dates: Apr 2014 to Aug 2015v10
  9. Primary and study completion dates: Apr 2013 to Apr 2014v9
  10. Enrollment target: estimated 150 to confirmed 177
    • Primary and study completion dates: Jan 2013 to Apr 2013
    • Interventions: Bortezomib (Velcade) (Drug) to Bortezomib (Velcade) (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Dexamethasone (Drug), Doxorubicin (Drug), Etoposide (Drug)…
    v8
  11. Primary and study completion dates: Jan 2012 to Jan 2013v7
  12. Re-verified, no change to tracked fieldsv6
  13. Primary and study completion dates: Jan 2011 to Jan 2012
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  14. Primary and study completion dates: Jan 2010 to Jan 2011
    • Site contact updated
    v4
  15. Re-verified, no change to tracked fieldsv3
  16. Primary completion date: Jan 2010
    • Site contact updated
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Trial Details
NCT Number NCT00572169
Lead Sponsor University of Arkansas
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 177 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov